Custom-Made vaccine targets tumors in Last-Resort patients

NCT ID NCT06963697

AVAILABLE Disease control Sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program offers a personalized vaccine made from each patient's unique cancer mutations (neoantigens) to help their immune system fight solid tumors. It is for patients aged 12 and older with local or metastatic cancer who have no other FDA-approved options and a low chance of 5-year survival. The vaccine is given along with an immune booster called poly-ICLC.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Personalized synthetic long peptide vaccine (neoantigen vaccine) plus poly-ICLC adjuvant
What this could lead to: If this vaccine works, it could help control tumor growth by training the immune system to attack cancer cells.
What could go wrong: This is an expanded access program, not a formal trial, so results are not systematically collected. The vaccine is personalized and early-stage, so effectiveness is uncertain and side effects may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Texas Oncology
AVAILABLE

Austin, Texas, 78705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.